Zymeworks ( (ZYME) ) has released its Q3 earnings. Here is a breakdown of the information Zymeworks presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zymeworks Inc., a clinical-stage biotechnology company, focuses on developing novel biotherapeutics for diseases like cancer, inflammation, and autoimmune conditions. In its third quarter of 2025, Zymeworks reported significant progress with its antibody-drug conjugate (ADC) platform, including encouraging Phase 1 data for ZW191 and the commencement of a clinical trial for ZW251. The company also achieved a $25 million development milestone from Johnson & Johnson and earned $1 million in royalties from Jazz and BeOne Medicines. Financially, Zymeworks reported a revenue increase to $27.6 million, driven by milestone achievements, although it still faced a net loss of $19.6 million. Despite this, the company completed $22.7 million in share repurchases, reflecting confidence in its long-term growth. Looking ahead, Zymeworks aims to leverage its strategic partnerships and robust pipeline to drive sustainable growth and shareholder returns, with a projected cash runway extending into the second half of 2027.